ROIV Roivant Sciences Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1635088 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY102.1%
TTM net income YoY7.9%
TTM EPS YoY-5.5%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,358.1%
Net margin-838.2%
FCF margin-81.2%
EBITDA margin-1,352.0%
Returns
ROE-8.2%
ROA-6.9%
ROIC (approx.)-16.0%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets7.6%
Debt / equity0.00x
Current ratio15.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.11x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue-7.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252026-03-31 | FY20242025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $8.26M | $29.05M |
| R&D expense | $681.81M | $550.41M |
| SG&A expense | $610.47M | $591.41M |
| Operating income | -$515.07M | -$1.00B |
| Pretax income | -$264.58M | -$681.59M |
| Income tax | $133.33M | $48.17M |
| Net income | -$299.77M | -$171.98M |
| EBITDA | -$511.72M | -$989.22M |
| EPS (basic) | -0.43 | -0.24 |
| EPS (diluted) | -0.54 | -0.24 |
| Weighted avg. shares (diluted) | 693.86M | 725.40M |
| Balance sheet | ||
| Cash & equivalents | $1.42B | $2.72B |
| Short-term investments | $2.87B | $2.17B |
| Current assets | $5.17B | $5.00B |
| PP&E, net | $11.99M | $12.06M |
| Total assets | $5.71B | $5.44B |
| Current liabilities | $281.24M | $149.41M |
| Total liabilities | $416.27M | $249.74M |
| Shareholders' equity | $4.53B | $4.69B |
| Shares outstanding | 720.35M | 695.94M |
| Cash flow statement | ||
| Operating cash flow | -$750.35M | -$839.45M |
| Capital expenditure | $8.21M | $4.60M |
| Free cash flow | -$758.56M | -$844.05M |
| Investing cash flow | -$682.33M | -$1.77B |
| Financing cash flow | $134.24M | -$1.22B |
| Depreciation & amortization | $3.35M | $14.07M |
| Stock-based compensation | $346.17M | $289.03M |
| Share buybacks | — | $1.29B |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.